FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
Xilio's second bailout
AbbVie follows Gilead in throwing Xilio a lifeline.
Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
Janux impresses again
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
